Value of drug level testing and antibody assays in optimising biological therapy

Biological therapy has been introduced in the late nineties and has significantly improved outcome of many chronic inflammatory conditions such as rheumatoid arthritis, spondylarthritis, Crohn's disease and ulcerative colitis (UC), psoriasis and psoriatic arthritis. The loss of efficacy of biological therapy over time, however, has proved to be the Achilles heel of this treatment. Loss of response is in most cases due to neutralising antibodies and low trough levels. Other reasons for lower response rates theoretically include other immune pathways driving the inflammation or absence of residual lesions although no studies have systematically investigated the reasons for loss of response in a consecutive cohort of patients. Mainly in patients with symptoms but no signs of inflammation in the blood, new imaging is recommended to rule out other reasons for loss of response such as symptoms due to irritable bowel syndrome, bile salt malabsorption and/or underlying strictures.1 ,2 Loss of response due to immunogenicity is usually managed clinically by decreasing the interval between infusions or injections, by increasing the dose, by adding immunomodulatory agents (methotrexate, azathioprine) or by switching within the same class to more humanised or human antibodies. However, these therapeutic interventions are often done in vain, only leading to higher costs and a potential increasing risk for side effects. Thus, despite interventions, a significant proportion of patients still drop-out per year.3 A drug can only exert its full effect when the lowest level (ie, level measured just before the next scheduled administration of medicine (=also called trough level (TL))) is sufficiently high. Thus optimal use of the drug implies the correct dosage which also means that peak levels and average levels should not exceed concentrations which are associated with increased toxicity. Therapeutic drug monitoring (TDM) with measurements of TL at regular intervals is routinely carried out …

[1]  Theo Rispens,et al.  Immunogenicity of biological therapeutics: from assay to patient , 2012, Current opinion in rheumatology.

[2]  S. Vermeire,et al.  Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. , 2010, Journal of Crohn's & colitis.

[3]  P. Rutgeerts,et al.  Anti-TNF induced skin manifestations in IBD patients : characterization and search for predisposing factors , 2011 .

[4]  G Van Assche,et al.  Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.

[5]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[6]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[7]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[8]  J. Gisbert,et al.  Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.

[9]  P. Goupille,et al.  Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study , 2011, Therapeutic drug monitoring.

[10]  K. Bendtzen,et al.  Clinical implications of variations in anti‐infliximab antibody levels in patients with inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[11]  P. Rutgeerts,et al.  405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease , 2010 .

[12]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[13]  Ann Gils,et al.  OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial , 2012 .

[14]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  L. Croner,et al.  565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD) , 2012 .